Health and Fitness Health and Fitness
Mon, June 7, 2010
[ 05:30 AM ] - Market Wire
Aoxing Pharmaceutical Company to Present at Jeffe .. Global Life Sciences Conference in New York City
[ 05:30 AM ] - Market Wire
AspenBio Pharma Updates on AppyScore(TM) FDA 510(k) Filing and Data Analysis
[ 05:00 AM ] - Market Wire
MDS to Release Second Quarter 2010 Financial Results
[ 04:30 AM ] - Market Wire
Aeterna Zentaris Presents Positive Efficacy and S .. ta for AEZS-108 in Ovarian Cancer at ASCO Meeting
[ 04:30 AM ] - Market Wire
Oncolytics Biotech(R) Inc. Collaborators Present .. I/II Trial Results in Advanced Solid Cancers with
[ 04:00 AM ] - Market Wire
Implant Sciences Appoints Monument Policy Group as Washington, D.C. Advisor
[ 04:00 AM ] - Market Wire
Hansen Medical to Present at the 9th Annual Needham Healthcare Conference
[ 03:30 AM ] - Market Wire
Cypress Bioscience, Inc. to Present at Jefferies 2010 Global Life Sciences Conference
[ 03:00 AM ] - Market Wire
Cellceutix Responds to Public Support by Expediti .. Two Required Safety Pharmacology Studies for Its
[ 01:34 AM ] - Market Wire
Exelixis Reports Updated Data from Multiple Clini .. nd mTOR Inhibitor XL765 (SAR245409) to be Present
[ 01:04 AM ] - Market Wire
Pr©sentation orale, l'ASCO, par l'Intergroupe Fr .. ne ©tude de phase III (IFM 2005 02) ©valuant le
[ 01:01 AM ] - Market Wire
Oral Presentation at ASCO from Intergroup Phase I .. tes Continuous REVLIMID® in Patients with Multip
[ 01:01 AM ] - Market Wire
Randomized Phase III Study Comparing REVLIMID® P .. (MPR) Compared to Autologous Stem Cell Transplant
[ 01:01 AM ] - Market Wire
Illumina Announces Purchase of HiSeqa" 2000 Units by the Broad Institute
[ 01:01 AM ] - Market Wire
In occasione della?incontro della?ASCO viene pres .. MID® in pazienti affetti da linfoma diffuso a gr
[ 01:01 AM ] - Market Wire
Beurteilung von REVLIMID® bei Patienten mit diff .. omen vom Keimzentrumstyp (GCB) oder anderer Typen
[ 01:01 AM ] - Market Wire
valuation de REVLIMID®chez les patients atteints .. s grandes cellules B de ph©notype GCB ou non-GCB
[ 12:18 AM ] - Market Wire
Presentati in occasione dell'incontro dell'ASCO i .. a combinazione REVLIMID® e Rituxan® per il Linf
[ 12:18 AM ] - Market Wire
La pr©sentation orale l'ASCO d'une ©tude interg .. 4) ©value le traitement ininterrompu au REVLIMID
[ 12:18 AM ] - Market Wire
In occasione della?ASCO vengono presentati i dati .. omalidomide in pazienti affetti da mieloma multip
[ 12:18 AM ] - Market Wire
Daten von Studie ber Pomalidomid bei Patienten mi .. efraktrem multiplem Myelom auf der ASCO vorgelegt
[ 12:18 AM ] - Market Wire
Presentan datos del estudio de pomalidomida en pacientes con mieloma mltiple refractario en ASCO
[ 12:18 AM ] - Market Wire
Pr©sentation l'ASCO des donn©es d'une ©tude su .. ment des patients atteints de my©lome multiple r
[ 12:18 AM ] - Market Wire
Pr©sentation, lors du congrs annuel de l'ASCO, d .. on du REVLIMID® et du Rituxan® pour le traiteme
[ 12:18 AM ] - Market Wire
Results from an Ongoing Phase I/II Trial of Oral INCB7839 Presented at ASCO
[ 12:18 AM ] - Market Wire
At ASCO, Oral Presentation from Intergroupe Franc .. ase III Study (IFM 2005 02) Evaluating Continuous
Sun, June 6, 2010
[ 11:27 PM ] - Market Wire
Pieris AG Appoints Chief Scientific Officer
Sat, June 5, 2010
[ 09:40 AM ] - Market Wire
Allos Therapeutics Reports New Data Demonstrating .. re Correlated with Prolonged Survival in Patients
[ 09:40 AM ] - Market Wire
Interim Positive Results From Phase 2b Brain Canc .. F-04948568 or CDX-110) Presented at 46th Annual A
[ 09:40 AM ] - Market Wire
Biogen Idec 2010 Annual Shareholder Meeting Webcast

Biogen Idec 2010 Annual Shareholder Meeting Webcast


Published on 2010-06-05 12:40:04 - Market Wire
  Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--Biogen Idec Inc. (NASDAQ:BIIB) announced today that its 2010 Annual Shareholder Meeting will be webcast live, via the internet, on Wednesday, June 9, 2010 at 9:00 a.m. EDT. To access the live webcast, please visit Biogen Ideca™s Investor Relations section ([ investor.biogenidec.com ]). An archived version of the webcast will be available following the meeting.

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit [ www.biogenidec.com ].

Contributing Sources